Study of Didox in Cancer Treatment
Author Information
Author(s): J. Carmichael, B.M.J. Cantwell, K.A. Mannix, D. Veale, H.L. Elford, R. Blackie, D.J. Kerr, S.B. Kaye, A.L. Harris
Hypothesis
Can didox, administered as a 36-hour infusion, be tolerated better than a 30-minute infusion in patients with metastatic malignant disease?
Conclusion
Didox administered by a 36-hour infusion was better tolerated than a 30-minute infusion, with minimal toxicity observed at the maximum tolerated dose.
Supporting Evidence
- The maximum tolerated dose was found to be 6 g/m2.
- No responses were seen in any of the patients treated.
- Toxicity was minimal up to the maximum tolerated dose with only minor hepatotoxicity observed.
Takeaway
Doctors tested a new cancer drug called didox to see if giving it slowly over a long time would be easier on patients than giving it quickly. It turned out that the slow method was much better for the patients.
Methodology
Patients with metastatic malignant disease were treated with didox via a 36-hour infusion, and pharmacokinetics were compared to a 30-minute infusion.
Limitations
The study had a small sample size and no clinical responses were observed.
Participant Demographics
{"total_patients":12,"male_female_ratio":"5:7","age_range":"39-72"}
Want to read the original?
Access the complete publication on the publisher's website